FindTrial
Sign In

Lasofoxifene

DRUG7 trials

Sponsors

Sermonix Pharmaceuticals Inc., Ligand Pharmaceuticals, QuantumLeap Healthcare Collaborative

Conditions

AngiosarcomaBone LossBreast CancerBreast NeoplasmsBreast TumorsEarly-stage Breast CancerHER2-negative Breast CancerHER2-positive Breast Cancer

Phase 2

Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation
CompletedNCT00143273
Ligand PharmaceuticalsOsteoporosis
Start: 2004-06-30End: 2006-03-31Updated: 2011-08-10
Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation
CompletedNCT00143273
Ligand PharmaceuticalsOsteoporosis
Start: 2004-06-30End: 2006-03-31Updated: 2011-08-10
The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
CompletedNCT00674453
Ligand PharmaceuticalsBone Loss
Start: 2004-09-30End: 2007-09-30Updated: 2011-08-10
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RecruitingNCT01042379
QuantumLeap Healthcare CollaborativeAngiosarcoma, Breast Cancer, Breast Neoplasms +8
Start: 2010-03-01End: 2031-12-01Target: 5000Updated: 2026-03-13
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
CompletedNCT03781063
Sermonix Pharmaceuticals Inc.Locally Advanced or Metastatic Breast Cancer
Start: 2019-09-20End: 2025-05-08Updated: 2026-01-28

Phase 3

Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)
CompletedNCT00141323
Ligand PharmaceuticalsOsteoporosis
Start: 2001-11-30End: 2007-12-31Target: 8556Updated: 2011-08-15
Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
CompletedNCT00163137
Ligand PharmaceuticalsOsteoporosis
Start: 2003-05-31End: 2005-10-31Updated: 2011-08-12
An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation
RecruitingCTIS2023-503708-10-00
Sermonix Pharmaceuticals Inc.Locally advanced or metastatic breast cancer
Start: 2024-02-20Target: 290Updated: 2025-10-27

Related Papers

Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
2026-03-25
Abstract PS3-11-10: Neoadjuvant HSP90 inhibition with ganetespib significantly improves distant relapse-free survival in I-SPY2 patients with HER2-negative breast cancer with low expression of immune genes and no DNA repair deficiency
Clinical Cancer Research2026-02-17
Abstract PS1-01-09: Real-time monitoring for drug-induced interstitial lung disease with Trastuzumab Deruxtecan and Rilvegostomig combination therapy prevents persistent, symptomatic disease: Safety insights from the I-SPY2.2 platform trial
Clinical Cancer Research2026-02-17
Abstract RF5-06: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial
Clinical Cancer Research2026-02-17
Abstract PS2-11-06: Quiescent-like phenotype characterizes treatment-resistant early-stage HER2-negative breast cancers and suggests novel therapeutic targets; analysis of over 2000 patients from the I-SPY2 trial
Clinical Cancer Research2026-02-17
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.
2025-10-24
Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
Frontiers in Oncology2025-07-24
A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images
Physics in Medicine and Biology2025-07-101 citations
Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.
2025-07-012 citations
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
Breast Cancer Research2025-06-233 citations
Abstract P2-01-23: A 140-gene Machine Learning Classifier Predicts Survival and Response to Chemotherapy and Immunotherapy in 2500 TNBC
Clinical Cancer Research2025-06-13
Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
Journal of Clinical Oncology2025-05-283 citations
Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).
Journal of Clinical Oncology2025-05-28
I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).
Journal of Clinical Oncology2025-05-28
Early adverse symptoms to predict response to treatment among patients in the I-SPY trial.
Journal of Clinical Oncology2025-05-28
Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO).
2025-05-15
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
Breast Cancer Research and Treatment2024-12-031 citations
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.
2024-11-299 citations
Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer.
2024-09-2710 citations
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Nature Medicine2024-09-1427 citations

71 more papers not shown